Cigna to end GLP-1 weight-loss coverage for its own employees on July 1

Cigna will stop paying for GLP-1 weight-loss drugs in the health plan it offers its own workers starting July 1, 2026. The drugs affected include Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) ^[1].

Staff were told in a June 1 email, and a company spokesperson confirmed the change ^[1]. It applies to the Cigna Group Medical Plan only — not to the policies Cigna sells to outside employers, and not to GLP-1 prescriptions written for type 2 diabetes ^[1].

"As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss," the spokesperson said ^[1].

A document circulated to employees says those already on the medications can buy them with cash through manufacturer websites or through TrumpRx ^[1]. Money spent that way will not be credited toward a deductible or toward the out-of-pocket threshold members must reach before their coverage starts paying ^[1].

For workers whose prescriptions had been approved, Cigna said it will cover older generic weight-loss medicines — phentermine, diethylpropion, benzphetamine and phendimetrazine — which its own materials describe as less effective than GLP-1s ^[1].

Prices for these drugs have been sliding in 2026. Novo's Wegovy pill and Lilly's oral Foundayo (orforglipron) arrived with prices starting at $149 a month for the lowest dose, and patients have been pushed increasingly toward paying cash ^[1]. Employers, meanwhile, have been trimming weight-loss benefits as spending on the drugs climbs ^[1]. GLP-1s work by imitating a hormone that keeps the stomach feeling full ^[1].

The Cigna Group also runs the health services unit Evernorth and the pharmacy benefit manager Express Scripts. It had 67,700 employees at the end of 2025, 88% of whom were based in the U.S. ^[1].

Why it matters for patients

For a Cigna employee who uses one of these drugs for weight loss, the decision comes down to paying out of pocket or stopping. Because cash purchases do not count toward a deductible, someone who pays cash could still owe the full deductible for other medical care later in the plan year ^[1].

Early research suggests people who quit these medicines often regain weight, and that the benefits tend to wear off within about two years ^[1]. The generics Cigna will cover are, by the company's own description, less effective than GLP-1s, so a switch may not produce the same result; the materials do not say how much weight people lose or regain on those older drugs ^[1].

Cigna has not disclosed how many of its employees take GLP-1s for weight loss or what the plan expects to save ^[1]. Whether other large employers will make similar changes to coverage for their own staff has not been reported.

What happens next

Employees now using a GLP-1 can refill their prescriptions through June 30, 2026 ^[1]. Coverage ends the following day, July 1 ^[1]. Cigna's statement covers only its employee plan, and the company has not said whether it will revisit the decision ^[1].